CStone Pharmaceuticals (HKG:2616) plans to issue up to 80 million shares to at least six investors under a placement deal at HK$2.933 apiece, according to a Wednesday filing with the Hong Kong bourse.
The shares comprise 5.86% of the entire share capital of the drug company following completion.
Net proceeds, estimated at HK$232.3 million, will be used for the development of cancer drugs and for other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.